• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
RETRACTED: An ATP-competitive inhibitor modulates the allosteric function of the HER3 pseudokinase.撤回:一种ATP竞争性抑制剂调节HER3假激酶的变构功能。
Chem Biol. 2014 Apr 24;21(4):453-458. doi: 10.1016/j.chembiol.2014.02.011. Epub 2014 Mar 20.
2
Targetable HER3 functions driving tumorigenic signaling in HER2-amplified cancers.靶向 HER3 功能可驱动 HER2 扩增型癌症中的致癌信号传导。
Cell Rep. 2022 Feb 1;38(5):110291. doi: 10.1016/j.celrep.2021.110291.
3
Targeting the HER3 pseudokinase domain with small molecule inhibitors.针对 HER3 假激酶结构域的小分子抑制剂。
Methods Enzymol. 2022;667:455-505. doi: 10.1016/bs.mie.2022.03.044. Epub 2022 Apr 18.
4
A small molecule inhibitor of HER3: a proof-of-concept study.一种 HER3 小分子抑制剂:概念验证研究。
Biochem J. 2020 Sep 18;477(17):3329-3347. doi: 10.1042/BCJ20200496.
5
Structural analysis of the EGFR/HER3 heterodimer reveals the molecular basis for activating HER3 mutations.表皮生长因子受体(EGFR)/人表皮生长因子受体3(HER3)异二聚体的结构分析揭示了激活HER3突变的分子基础。
Sci Signal. 2014 Dec 2;7(354):ra114. doi: 10.1126/scisignal.2005786.
6
ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation.ErbB3/HER3 细胞内结构域能够结合 ATP 并催化自身磷酸化。
Proc Natl Acad Sci U S A. 2010 Apr 27;107(17):7692-7. doi: 10.1073/pnas.1002753107. Epub 2010 Mar 29.
7
Bosutinib treatment for Philadelphia chromosome-positive leukemias.博舒替尼治疗费城染色体阳性白血病。
Future Oncol. 2014 Feb;10(2):179-85. doi: 10.2217/fon.13.268.
8
Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells.激酶抑制剂博舒替尼在原发性慢性髓性白血病细胞中的全球靶点概况。
Leukemia. 2009 Mar;23(3):477-85. doi: 10.1038/leu.2008.334. Epub 2008 Nov 27.
9
Inhibitor-induced HER2-HER3 heterodimerisation promotes proliferation through a novel dimer interface.抑制剂诱导的 HER2-HER3 异二聚体通过新的二聚体界面促进增殖。
Elife. 2018 May 1;7:e32271. doi: 10.7554/eLife.32271.
10
Structural insights into the ATP binding pocket of the anaplastic lymphoma kinase by site-directed mutagenesis, inhibitor binding analysis, and homology modeling.通过定点诱变、抑制剂结合分析和同源建模对间变性淋巴瘤激酶ATP结合口袋的结构洞察
J Med Chem. 2006 Sep 21;49(19):5759-68. doi: 10.1021/jm060380k.

引用本文的文献

1
Targeting HER2 by Combination Therapies.联合疗法靶向HER2
J Clin Oncol. 2018 Mar 10;36(8):808-811. doi: 10.1200/JCO.2017.77.1899. Epub 2018 Jan 30.
2
Structure of Fam20A reveals a pseudokinase featuring a unique disulfide pattern and inverted ATP-binding.Fam20A的结构揭示了一种具有独特二硫键模式和反向ATP结合的假激酶。
Elife. 2017 Apr 22;6:e23990. doi: 10.7554/eLife.23990.
3
Flicking the molecular switch underlying MLKL-mediated necroptosis.
Mol Cell Oncol. 2015 Jan 23;2(3):e985550. doi: 10.4161/23723556.2014.985550. eCollection 2015 Jul-Sep.
4
Effective treatment of HER2-amplified breast cancer by targeting HER3 and β1 integrin.通过靶向HER3和β1整合素有效治疗HER2扩增型乳腺癌。
Breast Cancer Res Treat. 2016 Feb;155(3):431-40. doi: 10.1007/s10549-016-3698-y. Epub 2016 Feb 9.
5
Nucleotide-binding mechanisms in pseudokinases.伪激酶中的核苷酸结合机制。
Biosci Rep. 2015 Nov 20;36(1):e00282. doi: 10.1042/BSR20150226.
6
Navigating into the binding pockets of the HER family protein kinases: discovery of novel EGFR inhibitor as antitumor agent.深入了解HER家族蛋白激酶的结合口袋:发现新型表皮生长因子受体(EGFR)抑制剂作为抗肿瘤药物
Drug Des Devel Ther. 2015 Jul 23;9:3837-51. doi: 10.2147/DDDT.S85357. eCollection 2015.
7
ATP binding to the pseudokinase domain of JAK2 is critical for pathogenic activation.ATP与JAK2假激酶结构域的结合对于致病性激活至关重要。
Proc Natl Acad Sci U S A. 2015 Apr 14;112(15):4642-7. doi: 10.1073/pnas.1423201112. Epub 2015 Mar 30.
8
Targeting HER3 by interfering with its Sec61-mediated cotranslational insertion into the endoplasmic reticulum.通过干扰HER3经Sec61介导的共翻译插入内质网来靶向HER3。
Oncogene. 2015 Oct 8;34(41):5288-94. doi: 10.1038/onc.2014.455. Epub 2015 Jan 26.
9
The Tribbles 2 (TRB2) pseudokinase binds to ATP and autophosphorylates in a metal-independent manner.Tribbles 2(TRB2)伪激酶以不依赖金属的方式与ATP结合并进行自身磷酸化。
Biochem J. 2015 Apr 1;467(1):47-62. doi: 10.1042/BJ20141441.
10
Pharmacological targeting of the pseudokinase Her3.靶向假激酶 Her3 的药理学研究。
Nat Chem Biol. 2014 Dec;10(12):1006-12. doi: 10.1038/nchembio.1658. Epub 2014 Oct 19.

本文引用的文献

1
EGFR lung cancer mutants get specialized.表皮生长因子受体(EGFR)肺癌突变体变得特异化。
Proc Natl Acad Sci U S A. 2013 Sep 17;110(38):15169-70. doi: 10.1073/pnas.1314719110. Epub 2013 Sep 10.
2
Mechanism for activation of mutated epidermal growth factor receptors in lung cancer.肺癌中突变型表皮生长因子受体的激活机制。
Proc Natl Acad Sci U S A. 2013 Sep 17;110(38):E3595-604. doi: 10.1073/pnas.1220050110. Epub 2013 Sep 9.
3
Architecture and membrane interactions of the EGF receptor.表皮生长因子受体的结构与膜相互作用。
Cell. 2013 Jan 31;152(3):557-69. doi: 10.1016/j.cell.2012.12.030.
4
Conformational coupling across the plasma membrane in activation of the EGF receptor.EGF 受体激活过程中跨质膜的构象偶联。
Cell. 2013 Jan 31;152(3):543-56. doi: 10.1016/j.cell.2012.12.032.
5
Oncogenic mutations counteract intrinsic disorder in the EGFR kinase and promote receptor dimerization.致癌突变抵消了 EGFR 激酶的固有无序性,并促进了受体二聚化。
Cell. 2012 May 11;149(4):860-70. doi: 10.1016/j.cell.2012.02.063.
6
Structural and spectroscopic analysis of the kinase inhibitor bosutinib and an isomer of bosutinib binding to the Abl tyrosine kinase domain.激酶抑制剂博舒替尼及其与 Abl 酪氨酸激酶结构域结合的异构体的结构和光谱分析。
PLoS One. 2012;7(4):e29828. doi: 10.1371/journal.pone.0029828. Epub 2012 Apr 6.
7
Comprehensive analysis of kinase inhibitor selectivity.激酶抑制剂选择性的综合分析。
Nat Biotechnol. 2011 Oct 30;29(11):1046-51. doi: 10.1038/nbt.1990.
8
A mechanism for tunable autoinhibition in the structure of a human Ca2+/calmodulin- dependent kinase II holoenzyme.一种人类 Ca2+/钙调蛋白依赖性激酶 II 全酶结构中可调自抑制的机制。
Cell. 2011 Sep 2;146(5):732-45. doi: 10.1016/j.cell.2011.07.038.
9
Cofactor-mediated conformational control in the bifunctional kinase/RNase Ire1.辅因子介导的双功能激酶/RNase Ire1 构象控制。
BMC Biol. 2011 Jul 6;9:48. doi: 10.1186/1741-7007-9-48.
10
The role of HER3, the unpretentious member of the HER family, in cancer biology and cancer therapeutics.HER3 在癌症生物学和癌症治疗学中的作用。
Semin Cell Dev Biol. 2010 Dec;21(9):944-50. doi: 10.1016/j.semcdb.2010.08.007. Epub 2010 Sep 9.

撤回:一种ATP竞争性抑制剂调节HER3假激酶的变构功能。

RETRACTED: An ATP-competitive inhibitor modulates the allosteric function of the HER3 pseudokinase.

作者信息

Littlefield Peter, Moasser Mark M, Jura Natalia

机构信息

Cardiovascular Research Institute, University of California, San Francisco, San Francisco, CA 94158, USA.

Department of Medicine, University of California, San Francisco, San Francisco, CA 94158, USA; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA 94158, USA.

出版信息

Chem Biol. 2014 Apr 24;21(4):453-458. doi: 10.1016/j.chembiol.2014.02.011. Epub 2014 Mar 20.

DOI:10.1016/j.chembiol.2014.02.011
PMID:24656791
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4018233/
Abstract

Human epidermal growth factor receptor 3 (HER3) is a receptor tyrosine kinase that lacks catalytic activity but is essential for cellular homeostasis due to its ability to allosterically activate EGFR and HER2. Although catalytically inactive, HER3 binds ATP tightly, hinting at a possible role of the nucleotide-binding pocket in modulating HER3 function. We report a structure of the HER3 pseudokinase bound to the ATP-competitive inhibitor bosutinib. Previously solved structures show that bosutinib can potently interact with multiple kinase domain conformations. In complex with HER3, bosutinib binds to yet another conformation, which is nearly identical to that observed in the HER3-ATP complex. Interestingly, occupation of the ATP-binding site by bosutinib improves the ability of HER3 to act as an allosteric activator of EGFR in vitro by increasing the affinity of the HER3-EGFR heterodimer in a membrane-dependent manner.

摘要

人表皮生长因子受体3(HER3)是一种受体酪氨酸激酶,缺乏催化活性,但因其能够变构激活表皮生长因子受体(EGFR)和人表皮生长因子受体2(HER2)而对细胞稳态至关重要。尽管HER3无催化活性,但它能紧密结合三磷酸腺苷(ATP),这暗示了核苷酸结合口袋在调节HER3功能中可能发挥的作用。我们报道了与ATP竞争性抑制剂博舒替尼结合的HER3假激酶的结构。先前解析的结构表明,博舒替尼能与多种激酶结构域构象发生有效相互作用。与HER3形成复合物时,博舒替尼结合到另一种构象上,这种构象与在HER3-ATP复合物中观察到的构象几乎相同。有趣的是,博舒替尼占据ATP结合位点后,通过以膜依赖的方式增加HER3-EGFR异二聚体的亲和力,提高了HER3在体外作为EGFR变构激活剂的能力。